Group 1 - The China Innovation Drug Industry Index (931152) has increased by 1.12%, with notable stock performances from companies such as Aosaikang (002755) up 10.02%, Jiuzhou Pharmaceutical (603456) up 6.41%, and Xinlitai (002294) up 4.43% [1] - Heng Rui Medicine announced a licensing agreement for its innovative drug SHR-A1811 with Glenmark Specialty, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, along with royalties based on sales [1] - According to Zheshang Securities, the domestic innovative drug sector in China is entering a phase of "engineer dividend" realization, with increasing recognition from multinational pharmaceutical companies (MNCs) leading to more frequent license-out transactions [1] Group 2 - Tianfeng Securities highlights that the Chinese innovative drug industry has formed a pyramid structure led by top enterprises, supported by a large number of quality companies, indicating strong sustainability in industry realization [2] - The underlying logic of the current cycle is that innovative drugs under development in China possess global competitiveness, with a shift from domestic sales to international data and transaction realization (license-out BD), opening up commercial space and leading to a healthier and more mature ecosystem [2] - The Jianxin Zhongzheng Innovation Drug ETF (159835) closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]

消息面上，7月28日，创新药企ETF(560900)跟踪指数成分股——药明康德发布半年报，公司上半年实现 营业收入207.99亿元，同比增长20.64%；归属于上市公司股东的净利润85.6亿元，同比增长101.92%。 其中，第二季度实现营业收入111.45亿元，这是公司历史上首次在第二季度营收突破百亿规模，归属净 利润48.89亿元，创历史同期新高。 信达证券指出，医药生物行业短期受基孔肯雅热疫情事件催化，叠加创新属性或迎来估值修复；诊断板 块前期新冠基数已消化，疫情或带来新需求。 创新药企ETF(560900)紧密跟踪中证创新药产业指数，中证创新药产业指数从主营业务涉及创新药研发 的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公 司证券的整体表现。 伴随AI驱动新一轮科技浪潮的兴起，摩根资产管理整合旗下"全球视野投科技"产品线，从主动管理到被 动投资产品，助力投资者从全球视野布局优质科技企业，把握时代浪潮下的投资机遇。 截至2025年7月29日收盘，创新药企ETF(560900)收涨3.15%，年内累计涨幅已达35.15%，换手37.88%， 市场交投活跃。跟踪 ...

Group 1 - The innovative drug ETF (560900) rose by 2.74% with a turnover of 30.12%, indicating active market trading [1] - The CSI Innovative Drug Industry Index (931152) increased by 2.82%, with notable gains in constituent stocks such as Tigermed (300347) up 10.32%, Jiuzhou Pharmaceutical (603456) up 10.01%, and WuXi AppTec (603259) up 6.30% [1] - The innovative drug ETF reached a new high of 1.019 yuan during the morning session, marking the highest price since the beginning of the year, with a half-day trading volume of 18.8945 million yuan, also a record since its listing [1] Group 2 - Huazhang Securities noted that high-value medical consumables have been under pressure from centralized procurement, but the market is now refocusing on low-priced medical devices and IVD sectors, with specific interest in artificial crystals, endoscopic consumables, orthopedics, and neurosurgery [2] - The innovative drug sector continues to gain traction, becoming one of the main market directions, with long-term investment value in innovative drugs, innovative devices, and AI healthcare [2] - The CSI Innovative Drug Industry Index is designed to reflect the overall performance of listed companies involved in innovative drug research and development, selecting no more than 50 representative companies [2]

Group 1 - The core viewpoint is that the innovative pharmaceutical ETF (560900) has shown significant growth, with a 2.09% increase and active trading volume, indicating strong market interest [1] - The innovative pharmaceutical ETF reached a new high in size at 55.51 million yuan as of July 25, with a notable increase of 3 million shares in the past week, leading the comparable funds [1] - The ETF's tracked index, the CSI Innovative Pharmaceutical Industry Index, consists of up to 50 representative listed companies involved in innovative drug research and development [2] Group 2 - The collaboration between Heng Rui Pharmaceutical and GSK involves a payment of 500 million USD for exclusive rights to the HRS-9821 project and potential milestone payments totaling approximately 12 billion USD [1] - The support from relevant departments for the development of innovative drugs and medical devices is expected to alleviate industry competition pressures, enhancing long-term value recognition in the market [2] - The rise of AI-driven technology is prompting investment opportunities in quality tech companies, as highlighted by Morgan Asset Management's integration of its global technology investment products [2]

Group 1 - The core viewpoint is that the Chinese innovative drug sector is gaining global recognition, with increasing clinical data presence at international academic conferences and rising BD authorization amounts and numbers, indicating enhanced global market acceptance of Chinese innovative drugs [2] - The innovative drug ETF (560900) has shown a strong performance, with a 1.57% increase as of July 28, 2025, and a 7.04% increase over the past two weeks, reflecting positive market sentiment [1] - The latest scale of the innovative drug ETF reached 55.51 million yuan, marking a six-month high, with a significant increase in shares by 3 million, leading the comparable funds [1] Group 2 - The support from medical insurance policies for innovative drugs is characterized by a "full chain, high intensity" approach, which includes accelerated inclusion of new drugs into the medical insurance catalog and optimized payment methods, further promoting rapid clinical application [2] - The innovative drug ETF closely tracks the CSI Innovative Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2] - The rise of AI-driven technology waves has prompted Morgan Asset Management to integrate its "Global Vision Investment Technology" product line, aiding investors in seizing investment opportunities in quality technology enterprises globally [2]

Group 1 - The China Securities Innovation Drug Industry Index (931152) increased by 0.55%, with notable stock performances including Zhenhua Cell (688520) up 16.46%, Rongchang Bio (688331) up 10.65%, and Aosaikang (002755) up 10.00% [1] - The Innovation Drug 50 ETF (159835) has shown a cumulative increase of 33.49% over the past year, indicating significant growth in its market share [1] - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, marking a pivotal step in the integration of commercial health insurance into the multi-tiered medical security system [1] Group 2 - Multiple policy releases are seen as significant for the development of innovative drugs, with the introduction of a commercial health insurance innovative drug directory expected to expand market opportunities and encourage pharmaceutical companies to enhance R&D efforts [2] - The domestic innovative drug industry is anticipated to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth, presenting dual opportunities for performance and valuation recovery [2] - The Innovation Drug 50 ETF closely tracks the China Securities Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug R&D to reflect the overall performance of the innovative drug sector [2]